Patent: 8,715,664
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 8,715,664
Title: | Use of human TNF.alpha. antibodies for treatment of erosive polyarthritis |
Abstract: | The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis. |
Inventor(s): | Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Wilmette, IL) |
Assignee: | AbbVie Biotechnology Ltd. (Hamilton, BM) |
Application Number: | 11/435,844 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,715,664 |
Patent Claims: | see list of patent claims |
Details for Patent 8,715,664
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2039-03-29 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2039-03-29 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2039-03-29 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2039-03-29 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 11/23/2015 | ⤷ Try a Trial | 2039-03-29 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 03/09/2016 | ⤷ Try a Trial | 2039-03-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |